within Pharmacolibrary.Drugs.ATC.L;

model L01EX06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.16999999999999998,
    adminDuration  = 600,
    adminMass      = 0.0125,
    adminCount     = 1,
    Vd             = 0.368,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005666666666666667,
    Tlag           = 1800
  );

  annotation(Documentation(
    info ="<html><body><p>Masitinib is a selective tyrosine kinase inhibitor targeting c-Kit, PDGFR, and other kinases. It is used mainly in clinical trials for oncology and inflammatory diseases and is approved for use in veterinary medicine for treating mast cell tumors in dogs. Masitinib is not currently approved for human use in the United States or European Union but has been under investigation for various cancers and disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult human volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Bellamy, F, et al., &amp; Hermine, O (2009). Pharmacokinetics of masitinib in cats. <i>Veterinary research communications</i> 33(8) 831–837. DOI:<a href=&quot;https://doi.org/10.1007/s11259-009-9231-6&quot;>10.1007/s11259-009-9231-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19533403/&quot;>https://pubmed.ncbi.nlm.nih.gov/19533403</a></p></li><li><p>Soria, JC, et al., &amp; Armand, JP (2009). Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. <i>European journal of cancer (Oxford, England : 1990)</i> 45(13) 2333–2341. DOI:<a href=&quot;https://doi.org/10.1016/j.ejca.2009.05.010&quot;>10.1016/j.ejca.2009.05.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19541476/&quot;>https://pubmed.ncbi.nlm.nih.gov/19541476</a></p></li><li><p>Jin, S, et al., &amp; Backman, JT (2024). In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 203 106884–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2024.106884&quot;>10.1016/j.ejps.2024.106884</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39218046/&quot;>https://pubmed.ncbi.nlm.nih.gov/39218046</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EX06;
